menu
    • menu
    [{"orgOrder":0,"company":"Neopharmed Gentili","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Divestment","leadProduct":"Berotralstat Hydrochloride","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neopharmed Gentili","amount2":0.26000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.26000000000000001,"dosageForm":"Capsule","sponsorNew":"Neopharmed Gentili \/ Neopharmed Gentili","highestDevelopmentStatusID":"15","companyTruncated":"Neopharmed Gentili \/ Neopharmed Gentili"},{"orgOrder":0,"company":"Neopharmed Gentili","sponsor":"Neopharmed Gentili","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mesoglycan","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Neopharmed Gentili","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neopharmed Gentili \/ Neopharmed Gentili","highestDevelopmentStatusID":"1","companyTruncated":"Neopharmed Gentili \/ Neopharmed Gentili"}]

    Find Clinical Drug Pipeline Developments & Deals by Neopharmed Gentili

    Menu

    Neopharmed Gentili

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neopharmed Gentili

                            Italy arrow
                            PREP
                            Not Confirmed

                            Neopharmed Gentili

                            Italy arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berotralstat Hydrochloride

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Recipient : BioCryst Pharmaceuticals

                            Deal Size : $264.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            BioCryst Announces Sale of European ORLADEYO (berotralstat) Business to Neopharmed

                            Details : Under the agreement, BioCryst sell will its European Orladeyo (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, business to Neopharmed Gentili.

                            Product Name : Orladeyo

                            Product Type : Miscellaneous

                            Upfront Cash : $250.0 million

                            June 27, 2025

                            Lead Product(s) : Berotralstat Hydrochloride

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Recipient : BioCryst Pharmaceuticals

                            Deal Size : $264.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Neopharmed Gentili

                            Italy arrow
                            OPRD
                            Not Confirmed

                            Neopharmed Gentili

                            Italy arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesoglycan

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Recipient : Societa Italiana di Chirurgia ColoRettale

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mesoglycan for Acute Hemorrhoidal Disease

                            Details : Mesoglycan is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Hemorrhoids.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 26, 2023

                            Lead Product(s) : Mesoglycan

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Recipient : Societa Italiana di Chirurgia ColoRettale

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Neopharmed Gentili

                            Italy arrow
                            OPRD
                            Not Confirmed

                            Neopharmed Gentili

                            Italy arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesoglycan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Recipient : Quovadis Associazione

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mesoglycan (Prisma®) Versus Placebo in Secondary Prevention of the Superficial Venous Thrombosis

                            Details : Mesoglycan is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Thrombophlebitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 12, 2018

                            Lead Product(s) : Mesoglycan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Recipient : Quovadis Associazione

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth